• A
  • |
  • A
  • Text size

Names Under Consideration

USAN Council's statement on the use of USAN as domain names:

A name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names Web site, shall be the effective equivalent of an intellectual property right on the part of the relevant entities.

Comments or protests should be addressed to Stephanie Shubat, USAN Program Director, American Medical Association, 330 North Wabash Avenue, Suite 39300, Chicago, Ill. 60611, or sent via email to USAN@ama-assn.org.

The following list of names for the drugs described are "under consideration" by the USAN Council:

June 2014

aglatimagene beradenovac antineoplastic
domeglicant treatment of diabetes
doncanatide treatment of GI disorder; inflammatory bowel disease
pegmodglutide treatment of diabetes and/or obesity
scrinvacumab antineoplastic
susquetide reduce intensity and duration of tissue damage caused by inflammation cascade and mucositis, increase clearance of bacterial infection
tofeglicant treatment of diabetes

May 2014

itarakinogene apaladenovec antineoplastic
fonadelpar treatment of patients with moderate to severe corneal epithelial wounds

April 2014

altiratinib antineoplastic
bulamuzumab treatment of muscle wasting disorders
guadecitabine antineoplastic
isactuzumab govitecan antineoplastic
labetuzumab govitecan treatment of cancer
landomuzumab treatment of muscle wasting disorders
noblatuzumab antineoplastic
sunakinra ocular surface inflammation
trevomumab treatment of muscle atrophy due to orthopedic disuse and sarcopenia